Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

mdma

  • Home
  •  
  • mdma



  • Most Read
  • Latest Comments
  • MDMA usage at University is through the roof as Emyria takes aim at mental health
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • MDMA usage at University is through the roof as Emyria takes aim at mental health
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • MDMA usage at University is through the roof as Emyria takes aim at mental health
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • MDMA usage at University is through the roof as Emyria takes aim at mental health
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • MDMA usage at University is through the roof as Emyria takes aim at mental health
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

  • Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
    • News

  • TGA gives green light to Emyria’s psychiatrists for MDMA therapy for PTSD
    TGA gives green light to Emyria’s psychiatrists for MDMA therapy for PTSD
    • News

  • Vape imports banned, Vitura introduces nicotine vaping products to tap new market
    Vape imports banned, Vitura introduces nicotine vaping products to tap new market
    • News

  • Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
    Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
    • News

  • MDMA usage at University is through the roof as Emyria takes aim at mental health
    • News

    MDMA usage at University is through the roof as Emyria takes aim at mental health

    Harbouring more MDMA than music festival goers, the University of Western Australia (UWA) is leading the way in research around the use of MDMA as a psychedelic medication. Clinical drug development and care delivery company Emyria (ASX: EMD) has today announced a partnership with UWA, confirming access to their library of MDMA- like compounds developed

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.